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Background: Cystic Fibrosis diagnosis is confirmed using sweat test. The aim of our study was to evaluate current techniques and methodologies
in use at Italian CF Care Centres.
Methods: A series of questions related to the performance of the sweat test was collected by all CF Care Centres in Italy. Answers were compared
with UK and NCCLS guidelines.
Results: 39/41 Centres replied to the questionnaire. A good adherence to guidelines was registered for storing samples before analysis in 90.9%,
while performing CF diagnosis by at least two sweat tests, and chloride analysis were reported respectively in 100% and 75.7% of Centres.
Some inconsistencies were registered for minimum acceptable sweat quantity and time to collect sweat inadequate in respectively 42.5% and
24.2% of Centres, while performing quality control procedures and referring to an external quality assessment scheme were found inadequate in
respectively 54.6% and 100%.
57.6% didn't provide any appropriate analytical ranges and only 15.1% of Centres offered proper information to patients/parents.
A report form, including sweat quantity, reference ranges and interpretation, was adequate only for 9.4 up to 41.4% of CF Centres.
Conclusions: Our study showed areas of inconsistencies in sweat testing current practices in Italy and highlights the need for evidence based
national guidelines to improve practice and management strategies.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Audit; Cystic Fibrosis; Sweat test; Diagnosis; CFTR1. Introduction
Sweat testing is a general term referring to the quantitative or
qualitative analysis of sweat available for establishing diagnosis
of Cystic Fibrosis (CF). It has been used for more than 50 years⁎ Corresponding author. Tel.: +39 339 1350708; fax: +39 081 5463933.
E-mail address: raia@unina.it (V. Raia).
1 Members of Italian Cystic Fibrosis Society Sweat Test Working Group. Bella Se
Antonella, Cystic Fibrosis Centre, Azienda Ospedaliera, Verona; Campagnano Pietr
Fibrosis Centre, Fondazione IRCCS, Policlinico Mangiagalli e Regina Elena, Milan
Gianfranco, Cystic Fibrosis Centre, Azienda Ospedaliera Meyer, Firenze; Minari Ro
Fabiana, Cystic Fibrosis Centre, Policlinico Umberto I°, Roma; Santostasi Teresa, C
Manuela, Genetic Laboratory, Fondazione IRCCS, Policlinico Mangiagalli e Regina
I°, Roma; Tardivo Irene, Cystic Fibrosis Centre, OIRM Sant’Anna, Torino; Vernice
(FG); Volpato Manola, Cystic Fibrosis Centre, OIRM Sant’Anna, Torino.
1569-1993/$ - see front matter © 2008 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2008.03.005for diagnosis of CF and remains the gold standard for the
complexity of the diagnosis of CF even in the genomic era [1,2].
Today a positive newborn screening for CF, clinical signs
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Table 1
Audit responses
Q1. Where do you perform sweat test? N Q11. How long do you collect sweat? N
a) In a clinic 13 a) b20 min 4
b) Stimulation and collection in a clinic, analysis in a laboratory 12 b) 20–30 min 7
c) In a laboratory 8 c) 30 min 16
d) 45 min 4
e) 60 min 4
Q2. How many patients are sweat-tested annually? N Q12. What is the minimum acceptable sweat quantity? N
a) 25–49 3 a) 10 uL 0
b) 50–99 7 b) 15 uL 6
c) 100–300 9 c) 50 mg 6
d) 300–500 5 d) 75 mg 6
e) N500 9 e) 100 mg 7
f) other 8
g) Non-minimum requirement 1
Q3. Do you have criteria which excludes a patient from undergoing a
sweat test? (select all that apply)
N Q13. What do you do when a sweat sample is not of sufficient
quantity for analysis?
N
a) Less than 1 week of age 10 a) Repeat the sweat collection procedure at another time 32
b) Less than 2 weeks of age 10 b) Continue the sweat collection until an adequate amount of
sweat is produced
0
c) Less than 4 weeks of age 15 c) Combine a specimen with another specimen to yield the
sufficient quantity
1




f) Acute illness 16
g) On systemic corticosteroids 17
h) Eczema at stimulation sites 21
i) Oedema 20
j) On oxygen by an open delivery system 11
Q4. Number of sweat collections carried out to make a diagnosis of CF N Q14. How do you store sweat samples before analysis? N
a) 1 0 a) At room temperature up to 3 days 3
b) 2 20 b) Immediate analysis 24
c) 3 10 c) At 2–8 deg C up to 2 days 1
d) N3 3 d) At 2–8 deg C up to 3 days 5
e) At −20 deg C up to 7 days 0
Q5. Do you provide any information to patients/parents concerning
sweat testing?
N Q15. Who is responsible for the analysis? N
a) No 1 a) Laboratory staff 22
b) Yes 32 b) Clinical staff 9
If yes, in which form? c) Others 2
a) Verbal 27
b) Written and verbal 5
c) Written 0
Q6. Do you obtain a written consent? N Q16. How is sweat analyzed in your Centre? (select all that apply) N
a) No 32 a) Conductivity using Wescor Sweat Check 7
b) Yes 1 b) Conductivity using Wescor Nanoduct 6
c) Chloride using a multitest automated analyzer 2
d) Chloride using a spectrophotometer 9
e) Chloride using a Orion skin measuring electrode 0
f) Chloride using CF Indicator Patch 0
g) Chloride using a titration instrument 13
h) Chloride using other 2
i) Sodium using flame photometer 3
j) Sodium using a multitest automated analyzer 6
k) Osmolality using …. 0
Q7. Who performs sweat collection? N Q17. How often do you analyze controls (3 levels: negative,
borderline, positive) for sweat testing?
N
a) Laboratory technologists 9 a) With every patient run all 3 levels 7
b) Laboratory physicians, biologists, chemists 8 b) With every patient run negative and borderline
(or positive) level
8
c) Nurses 14 c) Once a week 2 levels 3
d) Respiratory therapists 1 d) Once a month 2 levels 2
e) Physicians 8 e) Every 6 months 2 levels 3
f) Others 0 f) Never 9
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Q8. How many sweat tests are performed per person per year? N Q18. Do you participate in an EQA Scheme? N
a) b10 0 a) No 33
b) ≥30% 7 b) Yes 0
c) ≥50% 8
d) 100% 18
Q9. Are sweat tests (collection and analysis) routinely performed
from 2 sites (i.e., bilateral testing)?
N Q19. What are your laboratory reference ranges for sweat? N
a) Never 9 a) Chloride (⁎) Fig. 1a
b) Always 7 Negative
Only in these selected cases (select all that apply) Borderline
c1) 1 CFTR mutation 3 Positive
c2) Check of previous result 11 b) Sodium (⁎⁎) Fig. 1b
c3) Other 7 Negative
Borderline
Positive




Q10. What is the sweat collected into? N Q20. Who is responsible for the report? N
a) Macroduct coil 10 a) Absence of a written report 0
b) Pre-weighed gauze 5 b) Laboratory staff 11
c) Pre-weighed filter paper 17 c) Clinical staff 18
d) Collection tube 1 d) Others 4
e) Orion chloride measuring electrode 0
f) Cystic Fibrosis Indicator Patch 0
g) Nanoduct 2
Table 1 (continued )
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sweat chloride concentration is the analysis of choice even in
respect to genotype, particularly when the confirmation of CF
diagnosis is mandatory in those patients presenting with “atypical
CF” or CF related disorders. For this reason a much greater need
to standardize the collection and analysis of sweat has clearly been
expressed by several papers in the last few years [6,7,8,9].
The main topics of sweat test procedure involve sweat
stimulation, collection, and chloride analysis.
To provide guidance for the physician with the common aim of
further standardising both the collection and analytical components
of the sweat test recently the US National Committee for Clinical
and Laboratory Standards (NCCLS) and the UKMulti-disciplinary
Working Group have each published their own set of guidelines for
the performance of the sweat test [10,11] to improve its accuracy;
however, some criticism of their content suggests the need for
further concise recommendations.
At the same time individual surveys on sweat-testing
practices were published for the performance of the sweat test
in other countries such as USA [12,13], Sweden [14], Germany
[15], Canada [16], New Zealand [17], Swiss [18] and UK
[19,20]. The details of these studies were similar regardless of
the geographic area where the survey was carried out.
The collection and analysis of the sweat sample is recognised
as being technically demanding and subject to a number of pre-
analytical and analytical limitations related to unreliable meth-
odology as the currently accepted pilocarpine iontophoresis
sweat test method, inadequate sweat collection, inadequate
procedures and, occasionally, misinterpretation of the results.
Audit and feedback are commonly used as a quality improve-
ment tool in National Health Services.Aim of our study was to provide, for the first time in our
country, a survey on sweat test procedures currently performed at
Cystic Fibrosis Care Centres as well as to evaluate the adhesion to
accredited international sweat test guidelines.Moreover, on behalf
of the Italian Cystic Fibrosis Society (ICFS) the Sweat Test
WorkingGroupwould have assessed the opportunity of producing
a set of national guidelines to improve the performance of sweat
testing. These standardized procedures would have an impact in
the clinical approach for CF in both primary and secondary care.
2. Materials and methods
On behalf of the Italian Cystic Fibrosis Society (ICFS) a
multidisciplinary working group met with the purpose to collect
data on current practices in use at Italian CF Care Centres.
To address the problem, a questionnaire comprehensive of
20 quantitative and qualitative items (Table 1) was mailed in
April 2006 to all 41 Regional Referral Care Centres (RRCC)
and Support Services (SS) that provide care for the majority of
patients with CF in Italy.
Several quality indicators were selected among the pre-
viously mentioned recommendations [10,11,21] the quality of
sweat testing could be referred to. These key indicators
evaluated the methods for collection (Q 10, 11, 14) and analysis
of sweat samples (Q 16) as well as the reference analytical
ranges (Q 19). Other data were recorded such as information
provided to patients/parents (Q 5, 6) quality assurance (Q 2, 3, 4,
8, 9, 12, 13, 17, 18), responsibility for testing and interpretation
of results (Q 1, 7, 15, 20). All Centres applied the Gibson–
Cooke method (quantitative pilocarpine iontophoresis) as pre-
viously reported [1]. Members attending to the survey were
418 N. Cirilli et al. / Journal of Cystic Fibrosis 7 (2008) 415–422asked to attach a copy of their laboratory sweat-testing report
form.
3. Results
Replies were received from 39/41 CF Centres (95.1%). Six
CF Centres didn't perform sweat testing: 3 of them belonging
to CF adult Care Centres refer to their local paediatric CF
Centre for sweat testing, while 3 SS refer to their RRCC for
the test. The audit outcomes were therefore dated from 33
Centres. 29 Centres submitted usable sweat-testing report
forms. Replies to the questions and the report forms were
evaluated by the authors. The results are shown in Table 1
and Fig. 1a, b, c.Fig. 1. a. (⁎) Reference values for chloride. b. (⁎⁎) Reference va4. Comment
Some criticism was highlighted when analyzing answers
provided by Centres.
4.1. Demographics (Q 1,2,7,8)
Sweat was generally collected or completely performed in
the paediatric department or in the laboratory department (of
clinical chemistry) (Q 1). A wide variability was registered
related to one or more members of the staff performing sweat
test procedure (nurses, clinicians, laboratory technologists and
biologists) (Q 7). Three CF Care Centres (9.1%) didn't perform
adequate number of test/year according to internationallues for sodium. c. (⁎⁎⁎) Reference values for conductivity.
Fig. 1 (continued ).
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trained member provided at least 50% of tests/year (Q 8). There
are some evidences [10] indicating a tendency for a higher error
rates to be associated with the laboratories with low workloads.
Therefore international guidelines [10,11,21] recommend that
sweat collection and analysis should be performed in labora-
tories in which a large number of sweat tests are regularly
assessed.
4.2. Information to patients/parents (Q 5,6)
At least 5 Centres (15.1%) provided written and verbal
information concerning the sweat test procedure to patients/
parents, while all the others provided only verbal information
usually on demand (Q 5). Only 1 Centre required a written
consent form (Q 6).
By authors experience many patients and their families refer
to the Centre for a sweat test unaware of the indications and
procedures involved. Verbal description may be inadequate or
inconsistent and some members of the laboratory staff are
uncomfortable discussing a patient's question.Fig. 2. Tests per year per Centre.4.3. Sweat collection (Q 3,10,11,12,14)
None of the assessment criteria of the patient's condition
before testing was followed by 100% of Centres (Q 3). Several
factors regarding the clinical status of subjects can affect
sweating and sweat test results, so the adhesion to standardized
criteria is crucial for a correct procedure.
In the majority of Centres (96.9%), sweat was collected onto
gauze (15.1%) or filter paper (51.5%) or into Macroduct coils
(30.3%) (Q 10).
Duplicates were performed routinely at least in 7 Centres
(21.2%) (Q 9).
Sweat wasn't collected for an adequate time in 8 Centres
(24.2%) (Q 11).
Only 19 Centres (57.5%) took into account the minimum
sweat sample acceptable quantity of 75 mg or volume of 15 μl
(Q 12). Sweat electrolyte concentration is related to sweat rate:
at low sweat rates sweat electrolyte concentration decreases and
the opportunity for sample evaporation is increased. To ensure a
valid result the average sweat rate should exceed 1 g/m2/min.
The majority of questionnaires (96.9%) reported that sweat
collection was further carried out when initially failing to collect
an adequate sweat sample volume or quantity (Q 13).
Thirty Centres (90.9%) applied right procedures for storage
of sweat samples before analysis (Q 14).
4.4. Sweat analysis (Q 4,16,17,18)
According to the Consensus Statement of 1998 [2] all
Centres (100%) performed at least two sweat tests to confirm a
diagnosis of CF (Q 4).
Chloride was the most regularly analysed electrolyte
(75.7%); sodium was always analysed with chloride; conduc-
tivity was measured in 13 Centres (39.3%), in 7 of them
conductivity [22] was the only measure performed (Q 16). Some
Fig. 3. Methods for sweat test analysis.
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more than one method of analysis for the same constituent.
Methods used for sweat test analysis are showed in Fig. 3.
Only 15 Centres (45.4%) performed quality control (QC)
procedures in accordance with international guidelines (Q 17).
No one Centre referred to an external quality assessment
(EQA) scheme (Q 18).
Key factors in sweat analysis affecting accuracy and clinical
utility include the appropriate use of screening and confirmatory
tests and the institution of routine quality control procedures.
Screening tests for CF are qualitative tests which may or may
not quantify the amount of sweat collected and the results may
be reported as negative–borderline–positive, consistent or not
with CF or they may also provide a numerical concentration of
sweat analysis. For example, conductivity is considered a
screening test by the Cystic Fibrosis Foundation (CFF) [19].
Patients with a positive or borderline or negative screening test
value and the persistence of symptoms suggestive of CF shouldFig. 4. a: Example of chloride reference ranges for children less than 3 months of age. bundergo a confirmatory test, which consists of measurement of
chloride (with or without sodium). Regarding quality control
procedures, each Centre/Laboratory should analyse at least two
levels of quality controls each run and should participate to an
external quality assessment scheme.
4.5. Interpretation of results (Q 19)
Only 14 Centres (42.4%) provided appropriate analytical ref-
erence ranges for chloride (Q19), as stated byCFF guidelines [23].
Among all CF Centres 10 different analytical reference
ranges were applied for chloride, 4 for sodium and 7 for con-
ductivity. Only 4 Centres (12.2%) used age-related reference
intervals, but with different schemes. An example of what does
it mean in practice is reported in Fig. 4a and b. The sweat test
results must be correctly interpreted by the Laboratory staff and
the physicians in order to achieve a valid outcome. Laboratory
personnel, in the result-reporting phase of testing, should: Example of conductivity reference ranges for children less than 12 months of age.
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analytical reference ranges. The physician should interpret the
sweat test results taking in mind the patient's clinical
presentation and the sweat test should be repeated and/or
mutation analysis performed in presence of borderline or
positive results. Patients with unreasonable negative test results
despite of suggestive clinical picture, as well as patients
diagnosed with CF who do not follow the expected clinical
course, should be further evaluated.
4.6. Report forms
29 Sweat test report forms were available for authors'
analysis: the inclusion of the following items was evaluated [10]:
▪ full patient identification
▪ date of test
▪ date of report
▪ sweat weight/volume collected and minimum weight/
volume acceptable for local sweat test parameters
▪ analytical results
▪ reference ranges
▪ interpretation of results
All report forms (100%) included the full patient identifica-
tion and analytical results.
Sweat sample weight/volume was included only in 58.6% of
them and the minimum sweat sample acceptable weight/volume
only in 20.6%.
Analytical reference ranges were registered in 82.7% of
reports, while interpretation of results was present only in
58.6% of them.
While the responses to the reference intervals were
consistent, review of the report forms revealed significant
confusion concerning result-reporting.
Sweat test results should be reported appropriately, detailing
if the test represented a confirmatory test, or a screening test.
5. Discussion
The association of sweat chloride imbalance with alteration
in the CFTR gene has been extensively proven, thus sweat
chloride may be considered a measure of CFTR function. For
this reason sweat test, consisting of the measurement of chloride
after stimulation with pilocarpine, remains a key investigation
in the diagnosis of CF even in the genomic era.
During the last few years several articles highlighted the
need to take forward the practice of sweat testing to reflect the
changing demands for this diagnostic procedure.
Moreover with the rising incidence of atypical CF and
“CFTR-pathies” among adults and the wide spread of newborn
screening programs for CF the question of re-establishing age-
related reference intervals for sweat electrolyte concentration is
no longer deferring.
Previous systematic reviews identified international recommen-
dations to carry out local and national audit and generated questions
in an attempt to improve a healthcare service setting. Given theenormous implications of CF diagnosis, it is crucial that standard-
ised procedures must be followed in order to achieve accurate
sweat results useful to physicians tomake correct clinical decisions.
The Italian CF Centres whose experience we reviewed
revealed a fair/good adhesion to international guidelines in the
following areas:
– number of tests per Centre
– number of tests assessed per person per Centre
– number of tests to confirm a diagnosis of CF
– application of correct procedure of sample storage before
analysis
– application of correct procedure in presence of insufficient
sample
while major inconsistencies have been registered in the
following areas:
– application of correct reference analytical intervals accord-
ing to different ages
– application of correct QC procedures
– participation in an adequate EQA scheme program
– lack of patient/parents education and information con-
cerning sweat-testing practice and interpretation of results
In conclusion, our study showed that evidence based national
guidelines applied in our country would be desirable to improve
sweat-testing practices and management strategies. The adoption
of standardised methods shared by all CF Care Centres could
allow to improve current diagnostic skills. Such standardization
would have significant benefits among Italian people where more
than 70% of newborns undergo a screening procedure for CF.
Prospective aims of our working group will be to provide a
feedback to institutions participating in this audit, to promote
meetings and to deliver educational materials about sweat
testing.
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